eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 13
 
Share:
Share:
more
 
 
abstract:
Original paper

Correlation study of GAPDH, Bcl-2, and Bax protein immunoexpression in patients with colorectal adenocarcinoma

Marlena Brzozowa-Zasada, Józef Kurek, Adam Piecuch, Katarzyna Stęplewska

Gastroenterology Rev 2018; 13 (4): 322–331
Online publish date: 2018/12/11
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Colorectal cancer (CRC) is the third and second most commonly diagnosed cancer worldwide in males and females, respectively. Despite prominent progress in diagnosis and treatment, the recurrence rates are still high. A tumour hypoxic environment leads to an increase in glycolytic metabolism. The crucial intermediate component of glycolysis, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), could play a significant role in cancer progression. An increased level of GAPDH has been described in oncogene-induced transformation and anti-apoptotic function. In other studies, GAPDH has been involved in apoptosis induction.

Aim
We examined colorectal adenocarcinoma samples to assess the immunoexpression of GAPDH protein. We also evaluated the correlation between the expression of GAPDH protein and apoptotic parameters including expression of Bcl2 and Bax.

Material and methods
Paraffin sections were incubated for 60 min with primary antibody against GAPDH, Bcl-2, and Bax.

Results
Results of our study have shown that GAPDH expression in colorectal cancer is upregulated. We revealed significant positive correlation between expression of this protein and grade and size of tumour, and regional lymph node involvement. In the case of apoptosis-associated proteins, e.g. Bcl-2 and Bax, we found negative correlations between expression of these proteins and grade and size of tumour, lymphovascular invasion, and regional lymph node involvement. Finally, we demonstrated that GAPDH up-regulation is connected with down-regulation in Bcl-2 and Bax.

Conclusions
Up-regulation of GAPDH protein and down-regulation of Bcl-2 and Bax may result in increased of cancer.

keywords:

colorectal cancer, glycolysis, hypoxia, apoptosis, Bcl-2 proteins

references:
Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One 2013; 8: e78709.
Garza-Treviño EN, Said-Fernández SL, Martínez-Rodríguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int 2015; 15: 2.
Hsu PP, Sabatini DM. cancer cell metabolism. Warburg and beyond. Cell 2008; 134: 703-7.
Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 2016; 41: 211-8.
Ganapathy-Kanniappan, Geschwind JFH. Tumour glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013; 12: 152.
Guo C, Liu S, Sun MZ. Novel insight into the role of GAPDH playing in tumor. Clin Transl Oncol 2013; 15: 167-72.
Seidler NW. GAPDH: biological properties and diversity. Adv Exp Med Biol 2013; 985: 61-94.
Revillion F, Pawlowski V, Hornez L, Peyrat JP. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 2000; 36: 1038-42.
Colell A, Ricci J, Green DR, Ricci J. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 2009; 16: 1573-81.
Huang Q, Lan F, Zheng Z, et al. AKT2 suppresses GAPDH mediated-apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine 237 and decreasing its nuclear translocation. J Biol Chem 2011; 286: 42211-20.
Rondinelli RH, Epner DE, Tricoli JV. Increased glyceraldehydes-3-phosphate dehydrogenase gene expression in late pathological stage human prostate cancer. Prostate Cancer Prostatic Dis 1997; 1: 66-72.
Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 2001; 114: 1643-53.
Chuang DMM, Hough C, Senatorov VV. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2005; 45: 269-90.
Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 2000; 166: 29-43.
Brown JM, Attradi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231-7.
Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg 2006; 191: 517-26.
Collel A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 2009; 16: 1573-81.
Hang HS, Park YM, Hwang TS. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer. J Gastroenterol Hepatol 2006; 21: 1108-114.
Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009; 9: 307-19.
Lee MR, Ji SY, Mia-Jan K, Cho MY. Chemoresistance of CD133(+) colon cancer may be related with increased survivin expression. Biochem Biophys Res Commun 2015; 463: 229-34.
Schek N, Hall BL, Finn OJ. Increased glyceraldehydes-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res 1988; 48: 6354-9.
Phadke M, Krynetskaia N, Mishra A, Krynetskiy E. Accelerated cellular senescence phenotype of GAPDH-depleted human lung carcinoma cells. Biochem Biphys Res Commun 2011; 411: 409-15.
Tokunaga K, Nakamura Y, Sakata K, et al. Enhanced expression of glyceraldehydes-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 1987; 47: 5616-9.
Wang D, Zhang G. High expression of GAPDH is relevant to lung adenocarcinoma with low expression of the tumour suppressor gene deleted in liver cancer-1 (DLC1). Cancer Res 2014; 74 (19 Suppl): A2367.
Harada N, Yasunga R, Higashimura Y, et al. Glyceraldehyde-3-phosphate dehydrogenase enhancer transcriptional activity of androgen receptor in prostate cancer cells. J Biol Chem 2007; 282: 22651-61.
Zhang JY, Zhang F, Hong CQ, et al. Critical protein GAPDH and its regulatory mechanism in cancer cells. cancer Biol Med 2015; 12: 10-22.
Krajewska M, Moss SF, Krajewski S, et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinoma. Cancer Res 1996; 15: 2422-7.
Watson AJ, Merritt AJ, Jones LS, et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73: 889-95.
Belt EJT, Stockmann HBAC, Delis-Van Diemen PM, et al. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence. J Surg Oncol 2014; 109: 255-65.
Poincloux L, Durando X, Seitz JF, et al. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 2009; 18: 357-65.
Wincewicz A, Sulkowska M, Koda M, et al. Significant coexpression of GLUT-1, Bcl-xL, and Bax in colorectal cancer. Ann N Y Acad Sci 2007; 1095: 53-61.
Wincewicz A, Sulkowska M, Koda M, Sulkowski S. Cumulative expression of HIF-1-alpha, Bax, Bcl-xL and P53 in human colorectal cancer. Pathology 2007; 39: 334-8.
Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17: 1364-74.
Pryczynicz A, Gryko M, Niewiarowska K, et al. Bax protein may influence the invasion of colorectal cancer. World J Gastroenterol 2014; 20: 1305-10.
Huang CL, Kohno N, Inufusa H, et al. Overexpression of Bax associated with mutations in the loop- sheet-helix motif of P53. Am J Pathol 1999; 155: 955-65.
Ogura E, Senzaki H, Yamamoto D, et al. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expression in colorectal carcinomas. Oncol Rep 1999; 6: 365-9.
Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. Pathol Oncol Res 1999; 5: 273-9.
Pietrantonio F, Biondani P, Ciurlia E, et al. Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol 2013; 30: 610.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe